Current as of December 10, 2023
This is a randomized, double-blind, placebo-controlled trial of 24 months in which juvenile rheumatoid arthritis (JRA) patients will take either an oral calcium supplement of 1,000 mg elemental calcium per day or a matching placebo containing no calcium (Ca), plus one multivitamin per day. We hypothesize that patients receiving calcium supplementation will demonstrate at least a 10 percent greater increase in total body bone mineral density compared to those treated with placebo. We will evaluate patients at Children's Hospital Medical Center (CHMC) every 6 months for 2 years. We will also...
- Inclusion Criteria:
- JRA Diagnosis by American College of Rheumatology diagnostic criteria
- Age 6-18 years
- Exclusion Criteria:
- Taking calcium supplements or calcium- containing antacids
- Taken systemic corticosteroids in the prior 3 months
- Use of oral contraceptives
- Have been or currently pregnant
- Have another chronic illness that affects growth or bone mineralization (for example, Down's Syndrome, inflammatory bowel disease, steroid-dependent asthma)
- Fasting random urinary calcium/creatinine ratio > 0.2
The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Cincinnati, Ohio, United States
All reviews come from applied patients